| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Laboratorio di Patologia Clinica and
2
Divisione di Medicina Interna, Ospedale Civile, 30027 S. Donà di Piave (VE), Italy.
3
Istituto di Chimica Clinica, Azienda Ospedaliera S.
Maria della Misericordia, 33100 Udine, Italy.
4
Laboratorio di Microbiologia e Immunologia, Azienda
Ospedaliera S. Maria degli Angeli, 33170 Pordenone, Italy.
5
Laboratorio Analisi Chimico-cliniche e Microbiologia,
Ospedale Civile, 33053 Latisana (UD), Italy.
aAuthor for correspondence. Fax 39-0421-227571; e-mail nbizzaro{at}dacos.it.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Methods: Anti-CCP antibodies were determined in 330 serum samples: 98 from RA patients and 232 from controls, including patients with connective tissue diseases, other rheumatic diseases, viral infections, Lyme disease, autoimmune thyroiditis, cancer, and monoclonal gammopathy, and sex- and age-matched healthy subjects. Intra- and interassay CVs were 5–13% and 9–17%, respectively. Rheumatoid factor (RF) was also assayed in every sample, and results were compared to anti-CCP for sensitivity and specificity.
Results: At a cutoff value of 50 units, sensitivity was 41% (confidence interval, 31–50%) and specificity was 97.8% (95–100%). Anti-CCP-positive RA patients had a mean antibody concentration of 1100 units (range, 57–3419 units), and anti-CCP-negative RA patients and controls had mean values of 7.6 and 6.8 units, respectively (range, 1–39 units). The area under the ROC curve was 0.71 (95% confidence interval, 0.63–0.78). RF had a higher sensitivity (62%) and a lower specificity (84%) than anti-CCP. When the two antibodies were used together, specificity was 99.6%.
Conclusion: Anti-CCP antibody testing may be useful if performed concomitantly with RF assay to diagnose patients with suspected early RA.
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1–2% of the population in Western countries (1). RA is
diagnosed primarily according to clinical manifestations, and serologic
support is restricted to the determination of IgM rheumatoid factor
(RF), which has a low specificity because it may be found in healthy
elderly individuals, healthy immunized subjects, and patients with
other autoimmune diseases or chronic infections. Two other antibodies, anti-perinuclear factor (APF) (2) and anti-keratin antibodies (AKAs) (3), are considered possible diagnostic markers for RA; both recognize the antigenic protein filaggrin (4)(5). Although quite specific, these antibodies have never gained widespread popularity because of technical difficulties in substrate standardization and the subjective nature of the interpretation of the immunofluorescence tests.
Recently, a new serological test, the anti-cyclic citrullinated peptide (anti-CCP) ELISA was developed (6) and, based on preliminary data, it has an excellent specificity for the diagnosis of RA, especially in patients with early disease (7)(8).
Citrulline is an unusual amino acid resulting from an enzymatically posttranslationally modified arginine residue. Citrulline is present on a few human proteins, including filaggrin. Profilaggrin, which is present in the keratohyalin granules of human buccal mucosa cells, is proteolytically cleaved into several filaggrin subunits during cell differentiation. During this stage, the protein is dephosphorylated, and some arginine residues are converted into citrulline by the enzyme peptidylarginine deiminase (6).
In this study we evaluated the diagnostic and analytical performances of a new commercial ELISA for the detection of anti-CCP antibodies.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Among the RA patients, the variables recorded were age, gender, time from diagnosis, and laboratory data (antinuclear antibodies, IgM-, IgA-, and IgG-RF).
Anti-CCP antibodies were tested by ELISA (Immunoscan RA; EuroDiagnostica); RF was measured by laser nephelometry for the IgM isotype and by ELISA for the IgA and IgG isotypes; antinuclear antibodies were assayed by indirect immunofluorescence on HEp-2 cells. Each of these tests was performed and evaluated by operators who were blinded to other serological results and unaware of the patients’ clinical data.
To evaluate assay reproducibility, we also determine intra- and interassay imprecision; to this end, three samples containing low (100 units), intermediate (600 units), and high (2300 units) antibody concentrations were assayed six times in five independent analytical runs on different days.
Statistical analysis was performed using the SPSS 6.0 for Windows statistical package (SPSS). Means, SD, and confidence intervals (CIs) were used where appropriate. Nonparametric analyses were used to compare the two different groups of patients, and multiple regression models were used to assess the importance of the different variables relative to anti-CCP status. Two-sided P values <0.05 were considered significant throughout. ROC curves were used to calculate cutoff values for optimal sensitivity and specificity (10). Moreover, in preparing this report, the guidelines proposed by Bruns et al. (11) were followed.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
). Among these seven presumptive false positives, the patient
with MGUS, one of the two patients with AITD, and the one patient with
HCV infection had very high antibody concentrations of 1029, 1654, and
1395 units, respectively; the other four had lower concentrations
(66–154 units). These seven patients were all recalled, and a very
careful anamnesis and clinical work-up were done. After this inquiry,
it became evident that at least two of the patients with high antibody
concentrations, the one with MGUS and one with AITD, also had RA. The
HCV-positive patient died of colon cancer, but according to her general
practitioner, she had no symptoms or signs of RA. The three patients
with Lyme disease had no signs of RA, and the other AITD patient was
lost to follow-up. To avoid introducing a possible bias, the other 225
patients in the control group were recalled to verify the presence or
absence of RA symptoms. None manifested clinical signs of RA. However,
in 13 subjects follow-up was not possible; 5 patients with cancer and 2
with MGUS had died, and 6 subjects with AITD could not be located.
After this correction, the optimal cutoff value was determined by means
of the ROC curve (Fig. 2
). At a cutoff value of 50 units, sensitivity was 41% (CI,
31–50%) and specificity was 97.8% (CI, 95–100%; Table 1
). The area under the ROC curve was 0.71 (CI, 0.63–0.78).
|
|
|
antibody concentration
The assay reagent set included four calibrators from 50 to 3200
units; therefore, we could obtain data on antibody concentration as
well. Sample diluent was also included as the blank in each assay to
calculate the zero unit value. RA CCP-positive patients had a mean
antibody concentration of 1100 ± 764 units (range, 57–3419
units). RA CCP-negative patients had a mean value of 7.6 ± 6.7
units, and controls had a mean of 6.8 ± 5.1 units, with a range
of 1–39. The intraassay CV was 4.8–13%, and the interassay CV was
9–17%.
anti-CCP and RF
We also looked at RF prevalence: IgM-RF was positive in 62.2% (61
of 98) of the RA cases and in 16% (36 of 232) of controls. Therefore,
the sensitivity was 62% (CI, 57–67%) and specificity was 84% (CI,
82–87%).
IgA-RF, IgG-RF, and antinuclear antibodies, tested only in RA patients,
were positive in 45%, 33%, and 8% of the cases, respectively. In the
RA group, a good association was found between anti-CCP and IgM-RF
(
2, 13.8; P = 0.0002), IgA-RF
(2, 18.8; P = 0.00001), and
IgG-RF (2, 7.0; P = 0.008).
Anti-CCP antibodies alone were present in 5 cases, and IgM-RF was the
only antibody in 26. In the control group, there were 4 false-positive
cases for anti-CCP and 34 for IgM-RF; only 1 case was falsely positive
for both anti-CCP and IgM-RF antibodies (Table 2
).
|
We also compared the results of anti-CCP and IgM-RF for sensitivity and specificity. IgM-RF showed a higher sensitivity (62% vs 41%) and a lower specificity (84% vs 98%) than anti-CCP.
We also analyzed how these parameters would be affected if anti-CCP and
IgM-RF were combined in patients with only one of the two markers
(anti-CCP or IgM-RF) positive as well as in patients with both markers
(anti-CCP and IgM-RF) positive. When assayed together, the specificity
would increase from 98.7% for anti-CCP alone to 99.6% (Table 3
).
|
A significant correlation was also found between anti-CCP reactivity
and early arthritis (2, 8.2; P
= 0.004). We found no correlation between the presence or absence of
anti-CCP antibody and age or gender.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The recent development of synthetic peptides containing citrulline (6), an amino acid present in the filaggrin molecule and produced after its deimination, has enabled the development of an ELISA test; from preliminary data obtained during experimental trials, this test appears to have the same high specificity as APF and AKAs and to be able to eliminate the standardization problems related to immunofluorescence procedures. In this study, we evaluated the diagnostic accuracy of this new ELISA test, which is now commercially available. In the 98 RA subjects studied, the diagnostic sensitivity of the test was 41% and the specificity was 98%; these values confirm those obtained initially by Schellekens et al. (8).
To explain the low sensitivity, it must be considered that anti-CCP antibodies are a heterogeneous group of antibodies directed against different epitopes on the citrulline molecule, that each patient’s serum contains different subsets of antibodies, and that the synthetic peptide used in this assay represents a relatively small set of antigenic determinants that do not entirely encompasses the antigenic determinants present on the as yet unknown antigenic molecule in the joint (14).
The specificity is instead the most valuable aspect of this assay, so much so that it may be proposed as the most important examination in the diagnosis of RA. The net and surprising difference in antibody concentration between anti-CCP-positive and -negative samples is noteworthy. Indeed, positive samples showed high antibody concentrations, with a mean value of 1100 units, whereas negative samples were never higher than 39 units, with a mean value of 7–8 units. This is the first study to report quantitative data on anti-CCP antibody concentrations. Although our results require confirmation in larger studies, they show that a high antibody concentration is almost exclusively associated with RA.
It was also interesting to evaluate anti-CCP and RF behavior in RA patients in relation to the duration of disease. In patients with early arthritis (diagnosis made <1 year before this study), the correlation with anti-CCP was highly significant, thus indicating that this assay may be used even in the early phases of disease. This aspect is important because an early diagnosis of RA may modify the therapeutic strategy substantially, suggesting the use of more aggressive pharmacological treatments that can delay the progression of joint damage and thus substantially change the natural history of the disease (15)(16)(17).
Preliminary studies have demonstrated that the presence of anti-CCP antibodies also has a prognostic significance because it was shown that anti-CCP-positive patients develop significantly more severe radiologic damage than anti-CCP-negative patients (7)(14)(18). Therefore, serial assay of these antibodies could be useful in monitoring the clinical course.
In conclusion, we believe that the anti-CCP antibody assay is a very valuable tool for the diagnosis of RA. This ELISA test avoids many of the problems of the APF and AKA tests regarding quantification of the results and standardization of the assay. Its low sensitivity does not allow its use as a screening test, but because of its high specificity, especially when high antibody concentrations are present, it may become one of the most useful serologic tests for the diagnosis of RA. Moreover, when associated with RF determination, it provides nearly 100% specificity and thus could be helpful in the differential diagnosis of RA and other rheumatic diseases. In addition, this test may be very influential for the choice of the best therapeutic strategy in patients with recent-onset arthritis.
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  M. Labrador-Horrillo, M{a} A. Martinez, A. Selva-O'Callaghan, J. F. Delgado, X. Martinez-Gomez, E. Trallero-Araguas, J. L. Rodriguez-Sanchez, and M. Vilardell-Tarres Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy Rheumatology, June 1, 2009; 48(6): 676 - 679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-K. LIM, D.-H. SHEEN, Y. J. LEE, Y. R. MUN, M. PARK, and S.-C. SHIM Anti-Cyclic Citrullinated Peptide Antibodies Distinguish Hepatitis B Virus (HBV)-associated Arthropathy from Concomitant Rheumatoid Arthritis in Patients with Chronic HBV Infection J Rheumatol, April 1, 2009; 36(4): 712 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bizzaro, E. Tonutti, R. Tozzoli, and D. Villalta Analytical and Diagnostic Characteristics of 11 2nd- and 3rd-Generation Immunoenzymatic Methods for the Detection of Antibodies to Citrullinated Proteins Clin. Chem., August 1, 2007; 53(8): 1527 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nishimura, D. Sugiyama, Y. Kogata, G. Tsuji, T. Nakazawa, S. Kawano, K. Saigo, A. Morinobu, M. Koshiba, K. M. Kuntz, et al. Meta-analysis: Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis Ann Intern Med, June 5, 2007; 146(11): 797 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.B. Niewold, M.J. Harrison, and S.A. Paget Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis QJM, April 1, 2007; 100(4): 193 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Vannini, K Cheung, M Fusconi, J Stammen-Vogelzangs, J P H Drenth, A C Dall'Aglio, F B Bianchi, L E Bakker-Jonges, W J van Venrooij, G J M Pruijn, et al. Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: citrulline-dependent or not? Ann Rheum Dis, April 1, 2007; 66(4): 511 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Avouac, L Gossec, and M Dougados Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review Ann Rheum Dis, July 1, 2006; 65(7): 845 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Quinn, A. K. S. Gough, M. J. Green, J. Devlin, E. M. A. Hensor, A. Greenstein, A. Fraser, and P. Emery Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome Rheumatology, April 1, 2006; 45(4): 478 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. J. Harney, C. Meisel, A.-M. Sims, P. Y. Woon, B. P. Wordsworth, and M. A. Brown Genetic and genomic studies of PADI4 in rheumatoid arthritis Rheumatology, July 1, 2005; 44(7): 869 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G J Tobon, P A Correa, and J-M Anaya Anti-cyclic citrullinated peptide antibodies in patients with primary Sjogren's syndrome Ann Rheum Dis, May 1, 2005; 64(5): 791 - 792. [Full Text] [PDF]
|
|
|
|
|
|
P S Helliwell and W J Taylor Classification and diagnostic criteria for psoriatic arthritis Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii3 - ii8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C van Noord, H Hooijkaas, B C M Dufour-van den Goorbergh, P M van Hagen, P L A van Daele, and J P van de Merwe Diagnostic value of anti-cyclic citrullinated peptide antibodies to detect rheumatoid arthritis in patients with Sjogren's syndrome Ann Rheum Dis, January 1, 2005; 64(1): 160 - 162. [Full Text] [PDF]
|
|
|
|
|
|
I. E.A. Hoffman, I. Peene, H. Pottel, A. Union, F. Hulstaert, L. Meheus, K. Lebeer, L. De Clercq, L. Schatteman, S. Poriau, et al. Diagnostic Performance and Predictive Value of Rheumatoid Factor, Anti-citrullinated Peptide Antibodies, and the HLA Shared Epitope for Diagnosis of Rheumatoid Arthritis Clin. Chem., January 1, 2005; 51(1): 261 - 263. [Full Text] [PDF]
|
|
|
|
|
|
J-E Gottenberg, S Mignot, P Nicaise-Rolland, J Cohen-Solal, F Aucouturier, J Goetz, C Labarre, O Meyer, J Sibilia, and X Mariette Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome Ann Rheum Dis, January 1, 2005; 64(1): 114 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rej Clinical Chemistry through Clinical Chemistry: A Journal Timeline Clin. Chem., December 1, 2004; 50(12): 2415 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L De Rycke, I Peene, I E A Hoffman, E Kruithof, A Union, L Meheus, K Lebeer, B Wyns, C Vincent, H Mielants, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations Ann Rheum Dis, December 1, 2004; 63(12): 1587 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Kasapcopur, S Altun, M Aslan, S Karaarslan, A Kamburoglu-Goksel, S Saribas, N Arisoy, and B Kocazeybek Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis Ann Rheum Dis, December 1, 2004; 63(12): 1687 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Alessandri, M Bombardieri, N Papa, M Cinquini, L Magrini, A Tincani, and G Valesini Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF{alpha} therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement Ann Rheum Dis, October 1, 2004; 63(10): 1218 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Bodman-Smith, V. M. Corrigall, E. Berglin, H. R. Cornell, A. G. Tzioufas, C. P. Mavragani, C. Chan, S. Rantapaa-Dahlqvist, and G. S. Panayi Antibody response to the human stress protein BiP in rheumatoid arthritis Rheumatology, October 1, 2004; 43(10): 1283 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Spiritus, P Verschueren, R Westhovens, and X Bossuyt Diagnostic characteristics of a gelatin based Waaler-Rose assay (Serodia-RA) for the detection of rheumatoid factor Ann Rheum Dis, September 1, 2004; 63(9): 1169 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E R Vossenaar, T R D Radstake, A van der Heijden, M A M van Mansum, C Dieteren, D-J de Rooij, P Barrera, A J W Zendman, and W J van Venrooij Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages Ann Rheum Dis, April 1, 2004; 63(4): 373 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Dubucquoi, E Solau-Gervais, D Lefranc, L Marguerie, J Sibilia, J Goetz, V Dutoit, A-L Fauchais, E Hachulla, R-M Flipo, et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases Ann Rheum Dis, April 1, 2004; 63(4): 415 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lumbreras-Lacarra, J. M. Ramos-Rincon, and I. Hernandez-Aguado Methodology in Diagnostic Laboratory Test Research in Clinical Chemistry and Clinical Chemistry and Laboratory Medicine Clin. Chem., March 1, 2004; 50(3): 530 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D M Lee and P H Schur Clinical utility of the anti-CCP assay in patients with rheumatic diseases Ann Rheum Dis, September 1, 2003; 62(9): 870 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sanmarti, A. Gomez, G. Ercilla, J. Gratacos, M. Larrosa, X. Suris, O. Vinas, G. Salvador, J. Munoz-Gomez, and J. D. Canete Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting Rheumatology, September 1, 2003; 42(9): 1044 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Pinheiro, M. A. Scheinberg, M. Aparecida da Silva, and S. Maciel Anti-Cyclic Citrullinated Peptide Antibodies in Advanced Rheumatoid Arthritis Ann Intern Med, August 5, 2003; 139(3): 234 - 235. [Full Text] [PDF]
|
|
|
|
|
|
G. Salvador, A. Gomez, O. Vinas, G. Ercilla, J. D. Canete, J. Munoz-Gomez, and R. Sanmarti Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology, August 1, 2003; 42(8): 972 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bas, S. Genevay, O. Meyer, and C. Gabay Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis Rheumatology, May 1, 2003; 42(5): 677 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Bossuyt, J. B. Reitsma, D. E. Bruns, C. A. Gatsonis, P. P. Glasziou, L. M. Irwig, D. Moher, D. Rennie, H. C.W. de Vet, and J. G. Lijmer The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration Ann Intern Med, January 7, 2003; 138(1): W1 - W12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Bossuyt, J. B. Reitsma, D. E. Bruns, C. A. Gatsonis, P. P. Glasziou, L. M. Irwig, D. Moher, D. Rennie, H. C.W. de Vet, and J. G. Lijmer The STARD Statement for Reporting Studies of Diagnostic Accuracy: Explanation and Elaboration Clin. Chem., January 1, 2003; 49(1): 7 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Avcin, R Cimaz, F Falcini, F Zulian, G Martini, G Simonini, V Porenta-Besic, G Cecchini, M O Borghi, and P L Meroni Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis Ann Rheum Dis, July 1, 2002; 61(7): 608 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bas, T. V. Perneger, M. Seitz, J.-M. Tiercy, P. Roux-Lombard, and P. A. Guerne Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors Rheumatology, July 1, 2002; 41(7): 809 - 814. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
